Alan L. Rubino
Independent DirectorMr. Alan L. Rubino serves Chairman at AMO Pharma Ltd., since August 16, 2021. Mr. Rubino had been the President and Chief Executive Officer at RenovaCare, Inc. since November 15, 2019 until March 25, 2021. Mr. Rubino served as a Director of RenovaCare, Inc. since 2020 until March 25, 2021 and served as its Chairman since October 01, 2020 until March 25, 2021. Mr. Rubino serves as a Director of Genisphere, Inc. Mr. Rubino has been an Advisor of Emisphere Technologies, Inc. since October 15, 2019. Mr. Rubino served as the Chief Executive Officer, President and Director of Emisphere Technologies, Inc. since September 13, 2012 until October 15, 2019 and served as its Secretary. Mr. Rubino serves as a Principal of Watchung Partners. He has experience in pharmaceutical industry. His background includes executive responsibilities in both private and public companies encompassing business operations, business strategy, human resources, marketing, sales, corporate development and strategic planning. He served as Chief Executive Officer and President of New American Therapeutics, Inc. from October 2010 to August 2012. He served as the President of Akrimax Pharmaceuticals, LLC since February 2008 and also served as its Chief Executive Officer. He served as the President and Chief Operating Officer at Pharmos Corp. from November 14, 2005 to December 12, 2007. He served as Executive Vice President and General Manager of Sales Teams Business of PDI, Inc. from January 29, 2004 to April 18, 2005. He worked at Hoffmann-LaRoche for many years and held a variety of positions with broad responsibilities that encompassed Business Operations, Business Strategy, Human Resources and Sales and Marketing, including the launch of the first biotechnology product, Roferon-A(R). He serves as a Director of Aastrom Biosciences. He served as Senior Vice President of Business Operations of Hoffmann-LaRoche from 1997 to 2001 and served as its General Manager of Business Units. He served as Vice President for Business Operations and Corporate Officer of Hoffmann-LaRoche. He served as Senior Vice President of Pharmaceuticals Technology and Services Division of Cardinal Health. He joined Cardinal Health as part of the acquisition of BLPG, Inc. and served as its Executive Vice President & Managing Director. He serves as Director of Akrimax Pharmaceuticals. He has been an Independent Director of Vericel Corporation since September 30, 2005. He served as an Independent Director of SANUWAVE Health, Inc., since September 3, 2013 until June 3, 2021. Mr. Rubino has continued to expand upon a highly successful and distinguished career that included Hoffmann-La Roche Inc. where he was a member of Securities and Exchange Commission (SEC) corporate officer. He serves as a Director of Rutgers Business School of Newark and New Brunswick. He served as a Trustee of BioNJ Inc. He is a member of the Rutgers Business School Advisory Board. He attended executive programs at both Harvard Business School and the University of Lausanne. He received a B.A in Economics from Rutgers University in 1976 with a minor in Biology and Chemistry and has completed post-graduate educational programs at the University of Lausanne and Harvard Business School and several Executive Management Courses from Harvard Business School and IMEDE in Europe.
Positions
- Company NameVericel CorporationStock CodeVCELPositionIndependent DirectorColleagues
- DCDominick C. ColangeloCEO, President & Director
- RLRobert L. ZerbeIndependent Chairman & Lead Director
- JAJoseph Anthony MaraCFO & Treasurer
- MHMichael HalpinChief Operating Officer
- SCSean C. FlynnChief Legal Officer
- JMJonathan M. HopperChief Medical Officer
- HMHeidi M. HagenIndependent Director
- KFKevin F. McLaughlinIndependent Director
